背景:为了评估剂量学数据,早期毒性,在保乳手术后接受基于质子的辅助放疗(RT)的乳腺癌患者中,患者报告的美容结果。
方法:我们对我们的机构数据库进行了回顾性审查,以确定2015年至2020年接受保乳手术后接受基于质子的RT的乳腺癌患者。患者报告的美容结果被评为优秀,不错,公平,或者穷。治疗期间由治疗医师对早期毒性结果进行分级。审查剂量-体积直方图以获得剂量测定数据。
结果:我们确定了21例接受基于质子的辅助RT治疗的患者。整个乳房的中位剂量为46.8Gy(范围,40.0-50.4Gy)。目标体积包括17例患者(81%)的区域淋巴结。17名患者(81%)接受了肿块切除术。计划目标体积V95的中位数为94%(范围,77%-100%),V10071%(范围,60%-97%),V1102%(范围0%-18%),中位最大点剂量为115%(范围,105%-120%)。正中同侧乳腺V105为367.3cc(范围,0-1172cc),V110为24.1cc(范围,0-321.3cc)。2级和3级皮炎发生在62%和14%的患者中,分别。33%和10%的患者报告了2级和3级疼痛,分别。化妆品评估时的中位随访时间为27个月(范围,5-42个月)。4名患者(21%)报告了良好的美容效果,15名患者(79%)报告了良好或出色的美容效果。没有关于不良宇宙的报道。
结论:保乳手术后基于质子的辅助放疗具有良好的耐受性,急性毒性发生率可接受,患者报告的美容结果良好至优异。
To evaluate the dosimetric data, early toxicity, and patient-reported cosmetic outcomes in breast cancer patients treated with adjuvant proton-based radiotherapy (RT) after breast-conserving surgery.
We performed a retrospective review of our institutional database to identify breast cancer patients treated with breast-conserving surgery followed by proton-based RT from 2015 to 2020. Patient-reported cosmetic outcomes were graded as excellent, good, fair, or poor. Early toxicity outcomes were graded by the treating physician during treatment. Dose-volume histograms were reviewed to obtain dosimetry data.
We identified 21 patients treated with adjuvant proton-based RT. Median whole breast dose delivered was 46.8 Gy (range, 40.0-50.4 Gy). Target volumes included the regional lymph nodes in 17 patients (81%). Seventeen patients (81%) received a lumpectomy boost. The median planning target volume V95 was 94% (range, 77%-100%), V100 71% (range, 60%-97%), V110 2% (range 0%-18%), and median max point dose was 115% (range, 105%-120%). The median ipsilateral breast V105 was 367.3 cc (range, 0-1172 cc) and V110 was 24.1 cc (range, 0-321.3 cc). Grade 2 and 3 dermatitis occurred in 62% and 14% of patients, respectively. Grade 2 and 3 pain was reported by 33% and 10% of patients, respectively. Median follow-up at the time of cosmetic evaluation was 27 months (range, 5-42 months). Four patients (21%) reported fair cosmetic outcome and 15 patients (79%) reported good or excellent cosmetic outcome. No poor cosmesis was reported.
Adjuvant proton-based radiotherapy after breast-conserving surgery is well tolerated with acceptable rates of acute toxicities and a high rate of good-to-excellent patient-reported cosmetic outcomes.